| | | Top 10s | Current Top 10 by F1000 Factor All Time Top 10 by F1000 Factor Most viewed Top 10 (from all journals) Most viewed Top 10 (from specialty journals) Hidden Jewels
| Sections Covered | Cerebrovascular Disease | Cognitive Neurology & Dementia | Developmental & Pediatric Neurology | Epilepsy | Headache | Infectious Diseases of the Nervous System | Movement Disorders | Multiple Sclerosis & Related Disorders | Neuro-Oncology | Neuro-Ophthalmology & Neuro-Otology | Neurogenetics | Neuroimaging | Neuromuscular Diseases | Neurorehabilitation & CNS Trauma | Peripheral Neuropathies |
| Related SectionsAlzheimer's Disease | Disorders of Neurogastroenterology & Motility | Neuro-Endocrinology & Pituitary | Neurological Problems in Critical Care | Neuropsychiatric Disorders | Pain Management: Acute Clinical | Pain Management: Chronic Clinical | Pain: Basic Science | Schizophrenia & Other Psychoses |
|
|
|
|
|
| 1 |
|
| |
| 2 |
|
| |
| 3 |
|
| |
| 4 |
|
 |
Must Read |
| F1000 Factor 6.0 |
|
New Finding
|
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Segal BM, Constantinescu CS, …, Kasper LH, Ustekinumab MS Investigators Lancet Neurol 2008 Sep 7(9):796-804
[abstract on PubMed]
[related articles]
[full text]
[order article]
|
Selected by |
Roland Martin
with
Manuel Friese
Evaluated 14 Nov 2008
|
|
|
|
|
| |
| 5 |
|
| |
| 6 |
|
| |
| 7 |
|
| |
| 8 |
|
| |
| 9 |
|
| |
| 10 |
|
|